Real-world evidence of fruquintinib (Fruq) efficacy after regorafenib (Rego) and trifluridine–tipiracil (TAS-102) in refractory metastatic colorectal cancer (mCRC).Oluseyi Abidoye, Daniel H. Ahn, Christina Wu et al.|Journal of Clinical Oncology|2025Cited by 0
Overall survival based on sequencing of fruquintinib, regorafenib, and TAS-102 with or without bevacizumab in treatment-refractory metastatic colorectal cancer.Jennah Bauernfeind, Daniel H. Ahn, Oluseyi Abidoye et al.|Journal of Clinical Oncology|2025Cited by 0